Enable Cancer Therapy Personalization with Artificial Intelligence
Location: United States, California, Menlo Park
Total raised: $110M
Investors 6
| Date | Name | Website |
| - | Walden Cat... | waldencata... |
| - | Koch Disru... | kochdisrup... |
| - | cMy Ventur... | cmyventure... |
| 11.06.2023 | Breyer Cap... | breyercapi... |
| 23.10.2022 | AE Investm... | aeinvestme... |
| - | Coatue | coatue.com... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.02.2024 | - | $20M | - |
| 21.03.2023 | - | $90M | - |
Mentions in press and media 22
| Date | Title | Description |
| 14.08.2025 | FDA Authorizes ArteraAI Prostate: The First AI-Powered Tool for Prostate Cancer Prognosis | What You Should Know: – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ... |
| 18.06.2025 | Artera Launches Real-World Registry to Track AI’s Impact in Cancer Care | What You Should Know: – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the launch of its DIRECT-AI registry study. This new study will assess how the ArteraAI... |
| 09.05.2025 | AI Study Challenges Fears of Racial Bias in Prostate Cancer Care | What You Should Know: – Artera, a company developing multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the publication of a significant validation study in the JCO Clinical Cancer Inform... |
| 14.03.2024 | ArteraAI and Movember Announce New Relationship | Harnessing AI to accelerate personalized cancer treatment ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, today announced its continued work with Movember, the leading chari... |
| 02.02.2024 | ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy | The funding will support the international expansion and commercial growth of the company and its first-of-its-kind test ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, anno... |
| 01.02.2024 | Exclusive: ArteraAI nabs $20M to take personalized cancer care global | ArteraAI, a developer of AI tests to personalize therapy for cancer patients, raised $20 million in additional funding, CEO Andre Esteva tells Axios exclusively. Why it matters: Rising cancer costs have made personalized treatment modalitie... |
| 01.02.2024 | ArteraAI Raises $20M to Personalize Cancer Therapy With Multimodal AI | What You Should Know: – ArteraAI, a pioneer in multi-modal artificial intelligence (MMAI) for cancer treatment personalization, announced today an additional $20M in funding. – This latest round, backed by prominent investors like Prosperit... |
| 01.02.2024 | ArteraAI Announces $20M Financing Round | SAN FRANCISCO, CA, ArteraAI announced today that it has secured an additional $20 million. >> Click here for more funding data on Artera >> To export Artera funding data to PDF and Excel, click here ArteraAI, the develope... |
| 01.02.2024 | ArteraAI Raises Additional $20M in Funding | ArteraAI, a San Francisco, CA-based developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, raised additional $20M in funding. The round saw participation from Prosperity7 Ventures, Singapore-bas... |
| 22.12.2023 | AI is helping the healthcare industry and could transform the way patients get drugs and treatments | Tech AI is helping the healthcare industry and could transform the way patients get drugs and treatments Nicholas Fearn 2023-12-22T20:27:15Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email icon An... |
Show more